Haematologica
Journal
Overview
publication venue for
-
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry.
2024
-
Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies.
2024
-
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
2023
-
STAT5B mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophilia.
2023
-
Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.
2023
-
Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation..
108.
2023
-
Long non-coding RNA mitophagy and ALK- anaplastic lymphoma associated transcript: a novel regulator of mitophagy in T cell lymphoma.
2023
-
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients.
2023
-
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial.
2023
-
Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity.
2023
-
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy.
2023
-
Discordant SARS-CoV-2 spike protein receptor binding domain IgG and neutralization after B-cell depletion..
107.
2022
-
Extranodal presentation in limited-stage diffuse large Bcell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001..
107.
2022
-
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
2022
-
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies..
107.
2022
-
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients.
2021
-
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia..
106.
2021
-
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia..
106.
2021
-
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma.
2021
-
Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target..
106.
2021
-
Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma..
106.
2021
-
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma..
106.
2021
-
Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells..
106.
2021
-
Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or naturalkiller/T-cell lymphoma..
Online ahead of print.
2020
-
Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort..
105.
2020
-
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?.
105.
2020
-
Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients..
105.
2019
-
Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders..
105.
2019
-
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription..
105.
2019
-
Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values..
104.
2019
-
Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia..
104.
2019
-
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy..
104.
2019
-
Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma..
104.
2018
-
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia..
104.
2018
-
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States..
103.
2018
-
Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease..
103.
2018
-
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia..
103.
2018
-
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project..
103.
2018
-
Single-agent dabrafenib for BRAFV600E-mutated histiocytosis..
103.
2018
-
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results..
103.
2018
-
Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor..
102.
2017
-
The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope..
102.
2017
-
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome..
102.
2017
-
Bleeding risk of surgery and its prevention in patients with inherited platelet disorders..
102.
2017
-
Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT..
102.
2017
-
The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia..
102.
2017
-
Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes..
101.
2016
-
Donor and recipient sex in allogeneic stem cell transplantation: what really matters..
101.
2016
-
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival..
101.
2016
-
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I..
100.
2015
-
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia..
100.
2014
-
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients..
99.
2014
-
Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia..
99.
2014
-
Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics..
99.
2014
-
Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration..
99.
2014
-
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale..
99.
2014
-
Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up..
99.
2014
-
Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors..
99.
2013
-
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I..
98.
2013
-
STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma..
99.
2013
-
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies..
98.
2013
-
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies..
99.
2013
-
STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model..
98.
2013
-
Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial..
98.
2013
-
CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features..
98.
2013
-
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis..
98.
2013
-
Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells..
98.
2013
-
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia..
98.
2013
-
Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia..
98.
2013
-
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia..
98.
2013
-
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia..
98.
2012
-
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study..
98.
2012
-
Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine..
98.
2012
-
Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy..
97.
2012
-
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype..
97.
2011
-
Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera..
97.
2011
-
Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial..
96.
2011
-
Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens..
96.
2011
-
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type..
95.
2010
-
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma..
95.
2010
-
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib..
95.
2010
-
Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies..
94.
2009
-
The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells..
93.
2008
-
Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia..
93.
2008
-
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial..
93.
2008
-
Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin delta..
93.
2008
-
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience..
93.
2008
-
The pattern of genomic gains in salivary gland MALT lymphomas..
92.
2007
-
Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells..
90.
2005
-
Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses..
90.
2005
-
Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study..
88.
2003
-
Factor V Leiden mutation investigated by amplification created restriction enzyme site (ACRES) in PNH patients with and without thrombosis..
81.
1996
-
Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial..
105.
2020
-
Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a "grey zone" combination of myelodysplastic and myeloproliferative features?.
105.
2019
-
Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression..
105.
2019
-
Suppressive effects of anagrelide on cell cycle progression and the maturation of megakaryocyte progenitor cell lines in human induced pluripotent stem cells..
105.
2019
-
Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia..
105.
2019
-
Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1..
105.
2019
-
Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900..
104.
2018
-
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia..
103.
2018
-
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project..
103.
2018
-
Loss of 5-hydroxymethylcytosine is a frequent event in peripheral T-cell lymphomas..
103.
2017
-
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms..
103.
2017
-
Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin..
102.
2017
-
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study..
102.
2016
-
Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients..
102.
2016
-
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia..
101.
2016
-
Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation..
101.
2016
-
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure..
101.
2016
-
Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study..
101.
2015
-
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study..
100.
2015
-
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma..
99.
2014
-
JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug..
98.
2013
-
ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition..
96.
2010
-
Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials..
94.
2009
-
Immune surveillance of leukemia?.
90.
2005
-
Baseline disease risk and response to therapy in chronic myeloid leukemia: necessary predictive tools then and now..
90.
2005
-
A technique for detecting leukocyte-derived free radical production..
75.
1990
-
Acute myeloid leukemia shapes the bone marrow stromal niche in vivo.
2021
-
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.
2021
-
Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma.
2021
-
Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.
2020
-
Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms.
2019
-
Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma.
2019
-
Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study.
2018
-
Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort.
2018
-
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.
2017
-
Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma..
108.
2023
-
Cytomegalovirus-specific T cells following haploidentical transplants: reshaping a repertoire by half..
108.
2023
-
New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches..
104.
2019
-
Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials..
99.
2014
-
Extending the reach of nilotinib in chronic myeloid leukemia..
99.
2014
-
Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms..
99.
2014
-
Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations..
99.
2014
-
T315I, more or less, predicts for major molecular response: the devil is in the details!.
98.
2013
-
Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective..
95.
2010
-
Pathophysiology of Waldenström's macroglobulinemia..
95.
2010
-
Thrombopoietin receptor agonists: ten years later.
2019
-
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.
2016
-
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia.
2016
-
Epigenetic regulators and their impact on therapy in acute myeloid leukemia.
2016
-
Primary thrombocytosis in children.
2014
-
Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature.
2011
-
New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia.
1997
-
Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies.
1990
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)